BUSINESS INSIGHTS

Fuisz Pharma LLC Receives a Patent for a Non-Invasive Urological Device to Treat Benign Prostate Hyperplasia Symptoms (BPH)

FUISZ LLC | April 19, 2022

Fuisz Pharma
The first patent for Fuisz Pharma LLC's non-invasive urological device platform to alleviate symptoms of BPH, US 11,213,41, entitled "Device and Method for Reducing Urinary Retention," was issued via Fuisz LLC. Fuisz Pharma LLC is still looking for additional patent protection to go along with the one that was obtained.

The Fuisz device is non-invasive, simple to use, and has been shown to help initiate urination, minimize dribbling and nocturia, and decrease urine retention, all of which are frequent symptoms of BPH. The gadget can be used for easy and fast double voids.

The Fuisz device works on the principle of using a cool, rapidly transferred thermal transfer to induce the start of urination. Urination stream pressure requirements are dropped simultaneously.

The Fuisz gadget isn't intended to replace existing pharmaceutical or surgical treatments. It is meant to be used as an auxiliary non-invasive therapy to address symptoms.

Millions of American men suffer from urinary symptoms associated with BPH. These symptoms raise serious quality of life issues for patients. No male wishes to pause at a bathroom stall to initiate urination; be fearful of urgency during a trip to the store; or be deprived of a restful night by nocturia.”

Joseph Fuisz, the Managing Member of Fuisz Pharma

“The non-invasive Fuisz device offers substantial benefits for patients with BPH-type symptoms.”

“We are preparing to seek approval for the Fuisz device as a medical device.”

Spotlight

The United States is the number one medical device market in the world, accounting for more than 40% of all healthcare spending worldwide. The US has 310 million people and the highest per-capita spending on healthcare worldwide. Interested in learning more about the process to gain clearance and sell your products in the USA? This short video tells you how.

Spotlight

The United States is the number one medical device market in the world, accounting for more than 40% of all healthcare spending worldwide. The US has 310 million people and the highest per-capita spending on healthcare worldwide. Interested in learning more about the process to gain clearance and sell your products in the USA? This short video tells you how.

Related News

PHARMACY MARKET

Crosscope Inc Allies with Waleed Pharmacy for Pathology Solutions in Oman

Crosscope Inc. | April 11, 2022

Crosscope Inc. teams up with Waleed Pharmacy & Stores LLC. The latter focuses on fetching healthcare, hospital, and pharmaceutical solutions to the Sultanate of Oman, whereas Crosscope provides AI-enabled digital pathology software. Both have signed Memorandum of Understanding to facilitate a makeover in the Histopathology arena that uses Crosscope’s AI-enabled digital pathology platform. Moreover, both aim to bring pioneering technical solutions to Oman that allows commercial use that will reduce the country's cancer load, which is one of the chief health concern around the world. Oman is facing severity in terms of Cancer spread, as per World Health Organization. Crosscope Dx comes with an integrated workflow that works on the platform of vendor-agnostic digital pathology, which comes with comprehensive solutions for digital pathology. Moreover, Crosscope presents features such as advanced workflow, cohesive and easy to follow workflow solutions and open and scalable architecture designed for pathologists to decrease their workload, lessen the reversal time, guarantee quicker diagnosis, and a reduced outbreak of the disease in the region. Because of this partnership, Waleed Pharmacy will be Crosscope's official representative in Oman. Both firms plan to provide cancer diagnosis service providers with state-of-the-art comprehensive Digital Pathology Platforms, AI, and ML capabilities. They'll also look into all available options for collaboration, collaborating and using each other's knowledge, network, and know-how to improve the region's cancer diagnostics environment. "We are delighted to join forces with the Waleed Pharmacy group. Waleed Pharmacy's experienced team has a proven track record of delivering and deploying healthcare IT solutions in the Oman region and represents a perfect partner for Crosscope. By teaming up, we are confident that we have created the synergies to boost the development and commercialization of our digital pathology workflows," Dr. Jayendra Shinde, CEO of Crosscope Crosscope may collaborate with the region's most respected key opinion leaders in prestigious hospitals, clinical institutions, diagnostic chains, R&D labs, research organizations, pharma companies, and other organizations in the related space where the company's products provide clinical value to users.

Read More

PHARMACY MARKET

PCI Pharma Services Announces the Closing of Its Acquisition of LSNE

PCI Pharma Services | December 15, 2021

PCI Pharma Services a leading global contract development and manufacturing organizatio announced the closing of the previously announced acquisition of Lyophilization Services of New England, Inc. a premier contract development and manufacturing organization headquartered in Bedford, New Hampshire. This acquisition is a key step for PCI, as LSNE will expand PCI’s breadth of services as a global CDMO, building on its expertise in specialty manufacturing, clinical trial supply and pharmaceutical packaging. PCI is now able to offer integrated large and small molecule solutions for its clinical and commercial clients, including global manufacturing capabilities in complex formulations, high potency, sterile fill-finish, and lyophilization, an important manufacturing process commonly used with injectable and biologic therapies. Founded in 1997, LSNE has an impressive history of serving global pharmaceutical, biotechnology and medical device companies. LSNE is differentiated by its high-quality cGMP aseptic fill-finish capabilities, and expertise in and ability to scale lyophilization. LSNE brings to PCI five FDA-approved facilities in the U.S. and Europe with a sixth expecting approval early in the new year. The closing of this acquisition, along with the capital commitments for significant capacity expansion and PCI’s recently announced construction of a New England Clinical Center of Excellence, will also help create a centralized hub for its Northeast clients. The injectable CDMO market is a high-growth segment outpacing the overall pharmaceutical outsourcing market and PCI is making significant investments, like this acquisition, to respond to the evolving industry landscape. This is PCI’s fourth acquisition in three years, reinforcing the company’s commitment to add new capabilities and scale to help its clients continue bringing life-changing therapies to patients all over the world. About PCI Pharma Services PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.

Read More

BUSINESS INSIGHTS

CATO SMS Acquires Nuventra in order to Expand its Drug Development Offering Into Clinical Pharmacology

Nuventra, CATO SMS | May 27, 2021

CATO SMS, a global provider of regulatory and clinical research services, announced today the acquisition of Nuventra, Inc., to expand its offering into the critical area of clinical pharmacology. Nuventra, headquartered in Durham, North Carolina, is a leading company in clinical pharmacology science and services. The acquisition expands CATO SMS's portfolio of specialized solutions that help biopharmaceutical companies with drug development by providing a key set of skills targeted at significantly reducing development risk, costs, and timelines. CATO SMS now provides customers cutting-edge clinical pharmacology services such as strategic consulting, pharmacokinetics/pharmacodynamics (PK/PD), pharmacometrics (population PK), and biosimulation. Nuventra is well-known for its track record of transforming complex data into meaningful insights for over 650 biopharmaceutical companies across a wide range of therapeutic areas. Its team of scientific experts and senior consultants use the most advanced mathematical modeling tools in the industry to inform clinical design and predict trial outcomes. Nuventra's range of solutions include: • pharmacokinetics and pharmacodynamics (PK/PD), which describes the movement of drugs through the body from absorption to elimination (PK), as well as the body's biological response to drugs (PD) to determine optimal dosing paradigms, safety margins, and efficacy characteristics. • population pharmacokinetics (popPK and popPK/PD), which studies the variability in drug concentrations among individuals in a group of interest receiving clinically relevant doses of a drug. • clinical pharmacology strategic consulting, which includes overall and targeted clinical pharmacology strategy in support of marketing applications for drugs and biologics. • physiologically based pharmacokinetic (PBPK), which incorporates blood flow and tissue composition of organs to predict the absorption, distribution, metabolism, and excretion (ADME) of drugs. • quantitative systems pharmacology (QSP), which models the interplay of the drug (dose, dosing regimen, etc.) with target biology, using computational systems to characterize the interaction between drugs, biological systems, and disease processes. • model-informed drug development (MIDD), which uses modeling techniques to improve the decision-making process in drug development, thereby leading to clinical trial efficiencies and, in some cases, replacing trials altogether. About Nuventra Nuventra is the pharmaceutical industry's preferred provider of clinical pharmacology, pharmacokinetics, and pharmacometrics consulting services. Nuventra provides pharmaceutical companies and contracts research organizations (CROs) with unique access to a hands-on team of industry-leading consultants with extensive experience in complex studies and analyses. By taking complex pharmacokinetic and pharmacometrics concepts and making them understandable and usable for common sense drug development, we embrace the notion that simplicity and clarity lead to smart decisions. About CATO SMS CATO SMS is a provider of specialized clinical research solutions formed in 2019 by the merger of Cato Research and SMS-oncology. CATO SMS, with over 30 years of professional experience focusing on the needs of small and emerging biopharmaceutical companies, effectively designs and executes studies from strategy to approval in complex indications and modalities throughout a wide range of therapeutic areas, with a proven center of excellence in oncology. The regulatory, therapeutic, and operational expertise of CATO SMS enables the company to meet and exceed expectations.

Read More